Nothing Special   »   [go: up one dir, main page]

SG11202005251VA - Formulations of dengue virus vaccine compositions - Google Patents

Formulations of dengue virus vaccine compositions

Info

Publication number
SG11202005251VA
SG11202005251VA SG11202005251VA SG11202005251VA SG11202005251VA SG 11202005251V A SG11202005251V A SG 11202005251VA SG 11202005251V A SG11202005251V A SG 11202005251VA SG 11202005251V A SG11202005251V A SG 11202005251VA SG 11202005251V A SG11202005251V A SG 11202005251VA
Authority
SG
Singapore
Prior art keywords
formulations
dengue virus
vaccine compositions
virus vaccine
compositions
Prior art date
Application number
SG11202005251VA
Inventor
Michael Ryan
Sherrie-Ann Martin
Morrisa Jones
Justin Stanbro
Akhilesh Bhambhani
Jeffrey Thomas Blue
Heidi Joanne Pixley
Erin Green-Trexler
Lynne Ann Isopi
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SG11202005251VA publication Critical patent/SG11202005251VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11202005251VA 2017-12-07 2018-12-03 Formulations of dengue virus vaccine compositions SG11202005251VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762595842P 2017-12-07 2017-12-07
PCT/US2018/063541 WO2019112921A1 (en) 2017-12-07 2018-12-03 Formulations of dengue virus vaccine compositions

Publications (1)

Publication Number Publication Date
SG11202005251VA true SG11202005251VA (en) 2020-07-29

Family

ID=66750326

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005251VA SG11202005251VA (en) 2017-12-07 2018-12-03 Formulations of dengue virus vaccine compositions

Country Status (23)

Country Link
US (3) US20200390877A1 (en)
EP (1) EP3720487A1 (en)
JP (1) JP7042341B2 (en)
KR (1) KR102494651B1 (en)
CN (2) CN111447947B (en)
AU (1) AU2018381213B2 (en)
BR (1) BR112020011205A8 (en)
CA (1) CA3083772A1 (en)
CL (1) CL2020001463A1 (en)
CO (1) CO2020006836A2 (en)
CR (1) CR20200242A (en)
DO (1) DOP2020000098A (en)
EA (1) EA202091398A1 (en)
EC (1) ECSP20032084A (en)
GE (1) GEP20237539B (en)
IL (1) IL274897B1 (en)
JO (1) JOP20200140A1 (en)
MA (1) MA51060A (en)
MX (1) MX2020005857A (en)
NI (1) NI202000039A (en)
PE (1) PE20210654A1 (en)
SG (1) SG11202005251VA (en)
WO (1) WO2019112921A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020011205A8 (en) 2017-12-07 2023-02-07 Merck Sharp & Dohme FORMULATIONS OF VACCINE COMPOSITIONS AGAINST DENGUE VIRUS
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
EP4419205A1 (en) * 2021-10-20 2024-08-28 Solventum Intellectual Properties Company Phosphate and arginine containing compositions and the delivery of such compositions for virulence suppression
WO2024073362A2 (en) * 2022-09-29 2024-04-04 Board Of Regents, The University Of Texas System Methods and compositions for transport, storage, and delivery of nucleic acids and other molecules
EP4356925A3 (en) 2022-10-18 2024-05-01 Takeda Vaccines, Inc. Dengue vaccine formulation

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233566T2 (en) 1991-09-19 2006-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric and / or growth-inhibited flaviviruses
FR2702660B1 (en) * 1993-03-17 1995-05-24 Karl Simpson Stabilized therapeutic compositions and process for their preparation.
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
US6190859B1 (en) 1995-04-17 2001-02-20 The United States Of America As Represented By The Secretary Of The Army Method and kit for detection of dengue virus
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
BR122019026154B8 (en) 2001-05-22 2021-07-27 The Government Of The Us Secretary Department Of Health And Human Services attenuated dengue virus, pharmaceutical compositions comprising said virus, kit, tetravalent, live attenuated and inactivated dengue virus vaccines, and methods for preparing a dengue virus and a pharmaceutical composition
WO2003102166A2 (en) * 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
AU2003224810B2 (en) * 2002-03-26 2006-08-31 Immunex Corporation Methods of using Flt3-ligand in immunization protocols
BRPI0309631B1 (en) 2002-05-03 2021-07-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services TETRAVALENT IMMUNOGENIC COMPOSITION INCLUDING ATTENUED DENGUE VIRUS AND TETRAVALENT VACCINE INCLUDING SUCH COMPOSITION
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
CN101128216A (en) * 2005-01-05 2008-02-20 费城健康和教育公司 Delivery vehicles, bioactive substances and viral vaccines
CN101222936A (en) 2005-06-24 2008-07-16 英特威国际有限公司 Inactivated chimeric and related methods of use
BRPI0616879A2 (en) * 2005-10-04 2011-07-05 Alk Abello As solid vaccine formulation
EP2324850A1 (en) 2005-10-04 2011-05-25 Alk-Abelló A/S Solid vaccine formulation
LT2589602T (en) 2006-08-15 2016-10-10 The Government Of The U.S.A., As Repr. By The Secretary, Dept. Of Health & Human Services, The Nat. Inst. Of Health Development of dengue virus vaccine components
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CA2720570C (en) 2007-04-06 2022-10-04 Inviragen, Inc. Methods and compositions for live, attenuated dengue viruses
EP2143440A1 (en) * 2008-07-09 2010-01-13 Sanofi Pasteur Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
JP5548207B2 (en) * 2008-09-24 2014-07-16 メディミューン,エルエルシー Virus purification method
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
JP2012520084A (en) 2009-03-13 2012-09-06 レンチゲン コーポレイション Non-integrated retroviral vector vaccine
GB201002419D0 (en) * 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
SG10201801947YA (en) 2010-10-29 2018-04-27 Merck Sharp & Dohme Recombinant subunit dengue virus vaccine
JP2014515367A (en) 2011-05-26 2014-06-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Inactivated dengue virus vaccine
SI2811981T1 (en) * 2012-02-07 2019-08-30 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9974850B2 (en) * 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
US9254332B2 (en) * 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
SG11201510266SA (en) 2013-06-21 2016-01-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
US9782470B2 (en) 2013-10-16 2017-10-10 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CN105636609A (en) 2013-10-25 2016-06-01 白血球保健股份有限公司 A novel method for the production of stabile vaccines
WO2015093452A1 (en) 2013-12-16 2015-06-25 武田薬品工業株式会社 Microneedle
EP3089754B1 (en) * 2013-12-31 2021-04-21 Infectious Disease Research Institute Single vial vaccine formulations
WO2015130157A1 (en) 2014-02-28 2015-09-03 Universiti Malaya Enhancement of dengue virus production
BR112017013270A2 (en) 2014-12-22 2018-03-06 Merck Sharp & Dohme "dengue virus vaccine composition, methods for inducing a dengue immune response, reducing the likelihood of dengue infection, or preventing or alleviating dengue symptoms, and use of a dengue virus vaccine composition."
CN107949636B (en) * 2015-06-04 2021-11-09 香港大学 Live attenuated viruses and methods of production and use
US20180296663A1 (en) * 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
KR20180041761A (en) * 2015-09-30 2018-04-24 파나세아 바이오테크 리미티드 Stable attenuated recombinant dengue live vaccine
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
CA3018216A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
CA3020484A1 (en) * 2016-04-13 2017-10-19 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
TWI766876B (en) 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 Compositions and methods for stabilizing flaviviruses with improved formulations
EP3532093A1 (en) 2016-09-19 2019-09-04 Vaxess Technologies, Inc. Vaccine formulations with increased stability
WO2018183426A1 (en) 2017-03-30 2018-10-04 Merck Sharp & Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
KR20200088326A (en) 2017-10-16 2020-07-22 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 In particular, a stable vaccine composition comprising a live attenuated recombinant flavivirus and a method for manufacturing the same
BR112020011205A8 (en) * 2017-12-07 2023-02-07 Merck Sharp & Dohme FORMULATIONS OF VACCINE COMPOSITIONS AGAINST DENGUE VIRUS

Also Published As

Publication number Publication date
CA3083772A1 (en) 2019-06-13
GEP20237539B (en) 2023-09-11
CL2020001463A1 (en) 2020-09-25
KR20200096272A (en) 2020-08-11
WO2019112921A1 (en) 2019-06-13
EP3720487A1 (en) 2020-10-14
IL274897B1 (en) 2024-11-01
NI202000039A (en) 2020-09-24
AU2018381213A1 (en) 2020-06-11
KR102494651B1 (en) 2023-01-31
US20200390877A1 (en) 2020-12-17
IL274897A (en) 2020-07-30
JP2021505588A (en) 2021-02-18
BR112020011205A8 (en) 2023-02-07
US11883480B2 (en) 2024-01-30
ECSP20032084A (en) 2020-08-31
AU2018381213B2 (en) 2022-03-17
BR112020011205A2 (en) 2020-11-17
CN111447947B (en) 2024-01-12
JP7042341B2 (en) 2022-03-25
CR20200242A (en) 2020-07-17
US20230061673A1 (en) 2023-03-02
MA51060A (en) 2021-03-17
CO2020006836A2 (en) 2020-06-19
JOP20200140A1 (en) 2022-10-30
DOP2020000098A (en) 2020-08-31
US20240131144A1 (en) 2024-04-25
CN117752780A (en) 2024-03-26
EA202091398A1 (en) 2020-09-01
PE20210654A1 (en) 2021-03-31
CN111447947A (en) 2020-07-24
MX2020005857A (en) 2020-09-09

Similar Documents

Publication Publication Date Title
HK1250136A1 (en) Vaccine compositions having improved stability and immunogenicity
ZA201801035B (en) Vaccine compositions
IL274897A (en) Formulations of dengue virus vaccine compositions
SG11201701256RA (en) Vaccine compositions against dengue virus diseases
ZA201904505B (en) Universal influenza vaccine compositions
IL263574A (en) Calr and jak2 vaccine compositions
IL280332A (en) Composition containing influenza vaccine
GB201801566D0 (en) Methods and compositions for nanormulsion vaccine formulations
IL272857A (en) Formulations of copanlisib
ZA201801496B (en) Vlp stabilized vaccine compositions
EP3484511A4 (en) Vaccine compositions for treatment of zika virus
SG11202009147UA (en) Vaccine compositions
HK1255379A1 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
EP3305328A4 (en) Non-gelatin vaccine protectant composition and live attenuated influenza vaccine
GB2562241B (en) Vaccine compositions
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
ZA201807932B (en) Physiologically balanced injectable formulations of fosnetupitant
GB201703529D0 (en) Vaccine composition
GB201718251D0 (en) Vaccine Compositions
PT3678644T (en) Formulations of copanlisib
GB2564901B (en) Vaccine compositions
GB201906072D0 (en) Vaccine compositions
GB201809541D0 (en) Vaccine compositions
GB201805393D0 (en) Vaccine compositions
GB201712498D0 (en) Methods of producting vaccine compositions